Genomics BioSci & Tech. Co.Ltd.
Genomics BioSci & Tech. Co.,Ltd. operates as a genomic company in Taiwan. The company offers sequencing, synthesis, genomic, proteomic, and agency and sales services; reproductive health and cancer testing services; and contract development and manufacturing services. Genomics BioSci & Tech. Co.,Ltd. was founded in 2001 and is based in New Taipei City, Taiwan.
Genomics BioSci & Tech. Co.Ltd. (4195) - Net Assets
Latest net assets as of June 2024: NT$799.35 Million TWD
Based on the latest financial reports, Genomics BioSci & Tech. Co.Ltd. (4195) has net assets worth NT$799.35 Million TWD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.28 Billion) and total liabilities (NT$479.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$799.35 Million |
| % of Total Assets | 62.51% |
| Annual Growth Rate | 2.57% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 21.13 |
Genomics BioSci & Tech. Co.Ltd. - Net Assets Trend (2019–2023)
This chart illustrates how Genomics BioSci & Tech. Co.Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genomics BioSci & Tech. Co.Ltd. (2019–2023)
The table below shows the annual net assets of Genomics BioSci & Tech. Co.Ltd. from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | NT$765.51 Million | -2.99% |
| 2022-12-31 | NT$789.13 Million | +16.16% |
| 2021-12-31 | NT$679.34 Million | -25.16% |
| 2020-12-31 | NT$907.70 Million | +31.24% |
| 2019-12-31 | NT$691.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genomics BioSci & Tech. Co.Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 226.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$724.48 Million | 94.64% |
| Other Comprehensive Income | NT$-2.25 Million | -0.29% |
| Other Components | NT$150.56 Million | 19.67% |
| Total Equity | NT$765.51 Million | 100.00% |
Genomics BioSci & Tech. Co.Ltd. Competitors by Market Cap
The table below lists competitors of Genomics BioSci & Tech. Co.Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EBQLF
PINK:EBQLF
|
$38.37 Million |
|
C3 Metals Inc
OTCQB:CUAUF
|
$38.37 Million |
|
Halmont Properties Corporation
V:HMT
|
$38.37 Million |
|
Grupo Concesionario del Oeste SA
BA:OEST
|
$38.37 Million |
|
Sai Gon Mien Trung Beer JSC
VN:SMB
|
$38.35 Million |
|
Medical Developments International Limited
PINK:MDDVF
|
$38.35 Million |
|
Atrium Real Estate Investment Trust
KLSE:5130
|
$38.35 Million |
|
Ideal Bike
TWO:8933
|
$38.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genomics BioSci & Tech. Co.Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 789,128,000 to 765,513,000, a change of -23,615,000 (-3.0%).
- Net loss of 168,066,000 reduced equity.
- Dividend payments of 7,103,000 reduced retained earnings.
- Other comprehensive income decreased equity by 347,000.
- Other factors increased equity by 151,901,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-168.07 Million | -21.95% |
| Dividends Paid | NT$7.10 Million | -0.93% |
| Other Comprehensive Income | NT$-347.00K | -0.05% |
| Other Changes | NT$151.90 Million | +19.84% |
| Total Change | NT$- | -2.99% |
Book Value vs Market Value Analysis
This analysis compares Genomics BioSci & Tech. Co.Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$11.26 | NT$24.25 | x |
| 2020-12-31 | NT$10.99 | NT$24.25 | x |
| 2021-12-31 | NT$11.16 | NT$24.25 | x |
| 2022-12-31 | NT$12.42 | NT$24.25 | x |
| 2023-12-31 | NT$10.77 | NT$24.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genomics BioSci & Tech. Co.Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.43%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.48x
- Recent ROE (-21.95%) is below the historical average (-1.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 2.63% | 4.25% | 0.47x | 1.32x | NT$-50.99 Million |
| 2020 | 0.09% | 0.14% | 0.38x | 1.72x | NT$-66.60 Million |
| 2021 | 2.76% | 4.81% | 0.46x | 1.26x | NT$-49.20 Million |
| 2022 | 9.07% | 17.09% | 0.37x | 1.42x | NT$-7.32 Million |
| 2023 | -21.95% | -42.43% | 0.35x | 1.48x | NT$-244.62 Million |
Industry Comparison
This section compares Genomics BioSci & Tech. Co.Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genomics BioSci & Tech. Co.Ltd. (4195) | NT$799.35 Million | 2.63% | 0.60x | $38.36 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |